Shingles Vaccine Sales Exceed $1.1 Billion
GSK plc today announced Shingrix®, a vaccine against herpes zoster (shingles), had achieved a U.S. cumulative immunization rate that grew from 30% at the end of 2022 and has now reached 32% at the end of Q1'23.
And sales increased in the second quarter of 2023, reaching 880 million pounds (about $1.1 billion).
However, U.S. sales declined 10% in the quarter, impacted by unfavorable wholesaler and distributor inventory movements plus lower non-retail demand partly offset by strong retail growth and pricing.
On October 20, 2017, the U.S. FDA authorized Shingrix.
Furthermore, Shingrix is now available in 33 countries, with recent additions in India and Japan.
Emma Walmsley, Chief Executive Officer, GSK said in a press release on July 26, 2023, "We have made a strong start to 2023, with excellent performance across Vaccines, Specialty and General Medicines."
"We are very focused on our upcoming launches, including our potential RSV older adult vaccine, and on continuing to strengthen our pipeline – both organically with several positive late-stage read-outs already this year, and through targeted business development."
In the U.S., the CDC says an estimated 1 million people get shingles yearly. If you've ever had chickenpox, you can get shingles. Even children can get shingles. Your risk of shingles increases as you get older.
GSK says people should not receive Shingrix if they are allergic to its ingredients or have had an allergic reaction to a previous dose of Shingrix.